Millennium Management’s Enveric Biosciences ENVB Stock Holding History

Millennium Management’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25	Closed	-$49K	–	7166
2022 Q2	$49K	Buy	+25	New	+$53.2K	﹤0.01%	6210
2018 Q4	–	Hold	0	–	-$155K	–	3841
2018 Q3	–	Hold	0	–	–	–	3683

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Millennium Management's ENVB Position: Q3 2022 in Review

Millennium Management sold out of Enveric Biosciences (ENVB) in Q3 2022, closing a stake of 25 shares — an estimated $49K sold.

Millennium Management first reported a position in ENVB in Q2 2022 and held it in 1 quarter. The position peaked at $49K in Q2 2022. 9 funds tracked by Wall St. Rank hold ENVB as of Q3 2022.

Millennium Management reported no remaining Enveric Biosciences position as of Q3 2022 after selling out during the quarter.
Millennium Management sold 25 Enveric Biosciences shares in Q3 2022, an estimated $49K.
Millennium Management first reported a position in Enveric Biosciences in Q2 2022 and held it in 1 quarter.
Millennium Management's Enveric Biosciences position peaked at $49K in Q2 2022.
9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.